Source context: In 2026, Frontiers in Medicine published “Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of venous thromboembolism in patients with obesity: a real-world cohort study.” The paper is timely because incretin-related peptides remain one of the most watched areas in metabolic research, and this study looked at a serious vascular outcome rather than only weight or glucose markers.
What happened
The authors used the TriNetX global federated health research network to compare adults with obesity who initiated tirzepatide with adults who initiated GLP-1 receptor agonists between January 2022 and August 2025. The study used an active-comparator, new-user design and propensity-score matching to balance measured baseline differences between groups.
After matching, the analysis included 701,374 patients. The primary outcome was one-year incidence of venous thromboembolism, a category that includes deep vein thrombosis and pulmonary embolism. The paper also reported secondary outcomes including pulmonary embolism, deep vein thrombosis, and all-cause mortality.
Why people are paying attention
Tirzepatide sits in the broader incretin conversation because it targets GIP and GLP-1 receptor pathways. Public attention often compresses that whole field into simple GLP headlines, but the research literature is increasingly asking more specific questions: which receptor patterns are being studied, which outcomes are measured, and how real-world data compare with trial evidence.
This paper stands out because venous thromboembolism is not a cosmetic or casual endpoint. It is a serious health outcome, and the authors framed the question around comparative effectiveness rather than general interest in a peptide class. That makes the study useful to follow even though it should be read carefully.
What the study actually says
According to the PubMed abstract, tirzepatide initiation was associated with a lower one-year risk of venous thromboembolism compared with GLP-1 receptor agonists in the matched cohort. The reported hazard ratio for VTE was 0.90 with a 95% confidence interval of 0.83 to 0.98.
The abstract says the observed difference was driven by reductions in pulmonary embolism and all-cause mortality. For pulmonary embolism, the reported hazard ratio was 0.88. For all-cause mortality, the reported hazard ratio was 0.90. The study did not report a statistically significant difference for deep vein thrombosis, where the hazard ratio was 0.96 and the confidence interval crossed 1.0.
The authors also used negative-control outcomes and E-values to examine possible residual confounding. Those checks matter because real-world cohort studies can be large and informative, but they are still vulnerable to differences between patient groups that are not fully captured in the available data.
What it does not prove
This study does not prove that tirzepatide directly prevents venous thromboembolism, pulmonary embolism, or any other outcome. The authors describe the findings as associations and specifically note that causality cannot be established because the study is observational.
It also does not provide personal-use instructions or a reason for anyone to make medication decisions from a headline. The useful takeaway is narrower: a large real-world dataset produced a signal that researchers may want to test, challenge, and explain in future work.
Why it matters for peptide research conversations
For ThePeptides.org readers, the important part is the evidence structure. The paper names the comparator, the population, the matching strategy, the outcomes, and the limits. That is the kind of detail that separates a research conversation from a social-media claim.
The study also shows why incretin-related peptide discussions keep expanding. GLP-1, GIP, glucagon, and related metabolic pathways are now being discussed in connection with cardiovascular risk markers, kidney outcomes, liver disease, inflammation, vascular events, and other areas that go beyond the original public shorthand.
Keep reading
For broader category context, read GLP literacy. For a related peptide-family page on this site, see GLP-3 RT, which is a separate education page and not a tirzepatide product page.
Sources
- Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of venous thromboembolism in patients with obesity: a real-world cohort study. Frontiers in Medicine. 2026.
- Publisher DOI page: 10.3389/fmed.2026.1820366.
More peptide education
Browse the full Learning Center, or return to the homepage when you want the main path again.